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and 555MBq (15mCi) fixed dose regimens respectively. The data on demographic
(age, gender), clinical (presence of eye disease, the size/type of goiter) and biochem-
ical variables (serum Thyroid Stimulating Hormone -TSH) were obtained. Primary
outcome is to cure hyperthyroidism by rendering the patient either euthyroid or
hypothyroid within 6months of single dose RAI therapy. Statistical analysis was
carried out with SPSS version 15.0 and the level of statistical significance was taken
as P  0.05. RESULTS: Three (3) males (15%) and 17 females (85%) received RAI
therapy for Graves’ hyperthyroidism. Their mean age was 49.4 years (range of
25-75years). Fixed doses of 370MBq (10mCi) and 555MBq (15mCi) both produced a
response or cure rate of 100%. Overall, 65% and 35% were made hypothyroid
(TSH6.1mIU/L) and euthyroid (TSH0.21-6.0mIU/L) respectively. The incidence of
hypothyroidism was 66.6% with fixed dose of 370MBq (10mCi) and 62.5% with fixed
dose of 555MBq (15mCi) within 6months post RAI therapy. There was no significant
difference in the incidence of hypothyroidism produced by the two fixed doses of
RAI therapy. CONCLUSIONS: Radioactive iodine at fixed doses of 370MBq (10mCi)
and 555MBq (15mCi) was highly effective for the treatment of Graves’ hyperthy-
roidism, with a cure rate of 100%. Fixed doses of 370MBq (10mCi) and 555MBq
(15mCi) produced incidences of hypothyroidism of 66.6% and 62.5% respectively
within 6 months of RAI therapy which are not statistically different.
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OBJECTIVES: Metformin is an established first line treatment for type 2 diabetes
mellitus (T2DM) patients but intensification of oral antidiabetic therapy is usually
required over time. The Effectiveness of Diabetes control with vildaGliptin and
vildagliptin/mEtformin (EDGE) study compared effectiveness and safety of vilda-
gliptin and other oral antidiabetic drugs in 45868 worldwide patients with T2DM
inadequately controlled by monotherapy under real life conditions. Here we dem-
onstrate effectiveness results for patients receiving vildagliptin or sulfonylurea
(SU) add-on to metformin in Germany. METHODS: T2DM patients inadequately
controlled with current monotherapy are eligible after add-on treatment was cho-
sen by the physician based on patient’s need. Effectiveness was assessed by HbA1c
drop and by means of a composite endpoint assessing the proportion of patients
responding to treatment (HbA1c  7.0) without proven hypoglycemic event and
without significant weight gain (5%) after 12 months of treatment. RESULTS: In
total 8887 patients were enrolled in Germany; 5779 patients received metformin
vildagliptin (4960) or metforminSU (819). Mean age was 62.611.1 years, mean
T2DM duration was 5.84.9 years. Average BMI was 30.85.5 kg/m2. Mean baseline
HbA1c was comparable (vildagliptin:7.8%; SU:7.7%). After 12 months of treatment,
HbA1c decreased in both cohorts (vildagliptin:-0.69%; SU:-0.46%) but the drop was
significantly greater with vildagliptin compared to SU (	-0.23%; CI95% -0.32 -0.14;
p0.001). In the vildagliptin cohort, a higher proportion of patients reached the
composite endpoint (HbA1c7, no hypoglycemic events, no weight gain) when
compared to the SU cohort (vildagliptin:25.5%; SU:17.7%; p 0.001). The overall
recorded number of hypoglycemic events was low (vildagliptin:0.11%; SU:0.41%)
but almost 4-fold higher in the SU cohort when compared to the vildagliptin cohort.
CONCLUSIONS: In real life clinical practice in Germany, vildagliptin is associated
with a greater HbA1c-drop, less hypoglycemic events and a higher proportion of
patients reaching target HbA1c without hypoglycemia and weight gain compared
to SU.
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OBJECTIVES:No studies are available evaluating the impact of rapid-acting insulin
analogues on long-term outcomes. Our aim was to compare the use of rapid-acting
insulin analogues versus human regular insulin in relation to the occurrence of
diabetic complications in a cohort of diabetic patients. METHODS: Diabetic pa-
tients free of macrovascular disease at baseline were followed up for 3 years. All
patients were residents in Abruzzo Region of central Italy. The incidence of diabetic
complications was ascertained by hospital discharge claims. Patients receiving
human regular insulin were compared with those treated with rapid-acting insulin
analogues. HRs and 95% CIs of any diabetic complication and macrovascular, mi-
crovascular and metabolic complications were estimated separately using Cox pro-
portional hazard models adjusted for patients’ characteristics. Propensity score
matching was also used to adjust for significant difference in the baseline charac-
teristics between the two treatment groups. RESULTS: Overall, 2,286 patients were
included into the analyses: 914 in the human regular insulin group and 1,372 in the
rapid-acting insulin analogue group. During the 3-year follow-up, there were 286
incident events (31.3%) in the human regular insulin group and 235 (17.1%) in the
rapid-acting insulin analogue group, with a difference between the two treatment
groups in the cumulative HR for any diabetic complications that increased over
time (p0.0001). After adjustment for covariates, rapid-acting insulin analogues
had a HR (95% CI) of 0.63 (0.51-0.77) for any diabetes-related complication and HRs
of 0.62 (0.48-0.79) and 0.44 (0.27-0.73) for macrovascular and metabolic complica-
tions respectively, as compared with human regular insulin users. No difference
between the two groups was found for microvascular complications. All endpoint
results were supported by propensity score-based matched-pair analyses.
CONCLUSIONS:Our findings suggest that the use of rapid-acting insulin analogues
is associated with a lower risk of cardiovascular and metabolic complications com-
pared with human regular insulin use.
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OBJECTIVES: To assess the impact of hypoglycaemic events on BMI evolution and
HbA1c control in diabetes mellitus treated patients. METHODS: A retrospective
study was undertaken, based on the new French IMS Lifelink Diabetes Cohort,
investigating evolution of HbA1c, evolution of BMI and number of hypoglycaemia
events. Patient characteristics, glycemic control, therapeutic strategies, risk factors
and diabetes complications are introduced as descriptive variables. RESULTS: At
the end of May, more than 3 000 diabetic French patients (median and mean age
66.0, 56% men, 11.5% DT1 and 88.5% DT2) have been included in this cohort (4 000
patients expected in September and 5 000 at the end of the year). Average DT2
oldness is 10 years; 48% of the DT2 patients are treated with monotherapy, 36.0%
with a bi-therapy and 13.5% are receiving three and more drugs; median DT2 HbA1c
is 6.9%. Half of the DT2 patients are obese. 143 patients have today 5 months of
follow up in the database; on this period, 7% of the patients had at least one
hypoglycaemic event while evolution HbA1c and BMI rate are respectively -0.4%
(-0.06 points) and -0.14% (-0.07 points). Diabetes control of patients who had hypo-
glycaemic events has declined (0.07 points of HbA1c) while BMI has increased
(0.02 points); outcomes are opposite (with no statistical differences due to too low
sample) for diabetic patients without hypoglycaemic events (respectively, -0.07
points and -0.08 points). CONCLUSIONS:We have identified on a small sample size
a signal showing a weight increase and a worsening of HbA1c control in diabetes
patients with hypoglycaemic events. The IMS Lifelink Diabetes Cohort sample in-
crease expected until October 2012, as well as the longer duration of patient follow
up will allow an updated and more robust analysis of the possible impact of hypo-
glycaemic events on weight and HbA1c control.
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OBJECTIVES: To assess the effectiveness, tolerability and treatment adherence of
vildagliptin in type 2 diabetes patients under real-life conditions of care in France,
following a request by the French Health Technology Agency. METHODS: A repre-
sentative sample of type 2 diabetes patients initiating a treatment with vildagliptin
was enrolled in a 2 years follow up observational cohort in 2010 by a national
sample of endocrinologists and general practitioners. Data collected included so-
cio-demographic characteristics, clinical history, treatment and laboratory data.
We report here an interim follow up analysis. RESULTS: A total of 482 GPs and 84
endocrinologists have included 1,702 patients and 1,463 are analyzed in these in-
terim results up to 18 months (1,246 at 12 months and 700 at 18 months). 60% were
males, mean age was 63 (9) years, and mean disease duration was 7 (6.5) years.
The mean HbA1c level decreased rapidly from 7.8% (sd1.3) before vildagliptin
prescription to 7.1% (sd1.0) at 6 months and remained stable thereafter, respec-
tively 7.0% (sd1.1), and 6.9% (sd0.9) at 12 and 18 months after vildagliptin initi-
ation. The percentages of patients with alanine or aspartate aminotransferase
above 120 UI were 0.5% before vildagliptin prescription and respectively 0.3%, 0.5%
and 0.2% at 6, 12, and 18 months after vildagliptin prescription. The mean glomer-
ular filtration rate as calculated with the MDRD formula was 94.7 ml/minute before
vildagliptin prescription and 95.1, 95.3, and 95.1, respectively at 6, 12, and 18
months after vildagliptin prescription. The incidence of severe hypoglycemia (re-
quiring third party assistance) has been estimated at 0.24/ 100vildagliptin treated
patients years (CI95%[0.07,0.55]). The proportion of patients treated with vilda-
gliptin remained high over the course of the study: 96.6% (CI95%[95.6,97.5]) after 6
months and 91.6% (CI95%[90.1%,93.1%]) after one year.CONCLUSIONS:Vildaglip-
tin showed sustained effectiveness in terms of reduction in HbA1c over 18 months,
with a low incidence of hypoglycemia.
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OBJECTIVES: In spite of high prevalence of diabetes, there is a paucity of data on
epidemiology, clinical outcome measures, medication treatment pattern and
health care resource utilization among the Aboriginal people in Ontario. The ob-
jectives of this study were to follow a cohort of newly diagnosed Aboriginal people
with diabetes in South-Western Ontario (SWO) over a 5-year time horizon to doc-
ument their baseline characteristics, clinical outcomes and resource utilization.
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METHODS: Two-year of data on prescribed anti-diabetic medications were also
available for the analyses. Data from this cohort were compared to an age and
gender control group of Aboriginal individuals without diabetes. Regression anal-
yses were conducted to evaluate the impact of anti-diabetic medications on glyce-
mic levels and control after covariate adjustment (e.g. age, gender, baseline HbA1c).
RESULTS: A total of 323 individuals newly diagnosed with diabetes in 2002 were
identified. The mean HbA1c levels increased from 6.8% at time of diagnosis to 8.2%
at the end of the study in 2008. A similar trend was seen for fasting glucose levels.
After adjusting for covariate, the results of the regression analyses indicated that
continuous (versus no use) and intermittent (versus no use) use of anti-diabetic
drugs have no significant impact on 2-year HbA1c levels. Other clinical results
indicated that a large proportion of the Aboriginal people had uncontrolled hyper-
tension and hyperlipidemia. The average number of visits to physician, number of
hospitalization and the length of staying at hospital were higher among the Ab-
original people with diabetes compared to their control group. CONCLUSIONS:
Consistent with previous studies, these findings suggest that a minority of Aborig-
inal people in Southwestern-Ontario achieved optimal glycemic control.
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OBJECTIVES: Hypertension and obesity are associated with long-term complica-
tions of type 2 diabetes mellitus (T2DM). A systematic literature review assessed
the comorbidities’ prevalence in adults with T2DM. METHODS: Electronic data-
bases (PubMed, Embase, and Cochrane Library) were searched for articles pub-
lished in English between 2001 and 2012 and related to T2DM plus hypertension
and/or obesity. Bibliographies of included studies were also examined. Data were
analyzed by continental regions (Africa, Asia, Europe, North America, Oceania, and
South America). RESULTS: We reviewed 2,688 abstracts and identified 92 relevant
observational studies. Hypertension was defined by varying blood pressure cut-
points (e.g., 140/90, 130/85, or 130/80 mmHg) or sometimes not clearly defined. The
prevalence rates for hypertension were: Africa, 38.5%-80%; Asia, 13.6%-85.8%; Eu-
rope, 29.3%-95%; North America, 52%-70.9%; Oceania, 79%-85%; South America,
50%-90.0%; and multiregional (Europe and Africa), 75.8%. Cutpoints for defining
obesity by body mass index (BMI) or waist circumference (WC) also varied among
the studies. The prevalence rates of obesity among adults with T2DM, were: Africa,
11.9%-54.6%; Asia, 20.1%-83.45%; Europe, 22.1%-96.9%; North America, 38%-62.4%;
Oceania, 46%-51%; South America, 30.5%-80.6%. In Europe, the combined preva-
lence of obesity defined by BMI or waist-to-hip ratio was 50.9%-98.6%. Limited data
suggest common comorbidity of both hypertension and obesity in adults with
T2DM. CONCLUSIONS: Across the globe, hypertension and obesity, separately or
together, are common comorbidities in adults with T2DM. Accurately quantifying
their prevalence in regional populations will help prioritize health care efforts for
managing these comorbidities, with a goal of reducing their long-term health and
cost consequences.
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OBJECTIVES: According to the U.S. Department of Veterans Affairs (VA), roughly
25% of veterans have been diagnosed with diabetes, and the mortality rate aver-
ages 5% per year compared to 2.6% in patients without diabetes. The goal of this
study was to examine the geographic variation in the annual prevalence of diabe-
tes mellitus (DM) in the U.S. veteran population. METHODS: The study sample was
extracted from the Veterans Health Administration (VHA) Medical SAS datasets
from 2006 through 2011. All patients diagnosed with DM throughout the study
period were identified using International Classification of Diseases 9th Revision
Clinical Modification (ICD-9-CM) diagnosis codes 250.xx, 357.2x, 362.0x and 366.41.
The change in prevalence over the 6-year period was assessed and the variation in
DM prevalence was tested by U.S. state. Statistical analyses were performed using
SAS v9.3 software.RESULTS: Puerto Rico had the highest regional prevalence of DM
with an increase from 23.79% in 2006 to 26.33% in 2011, while the western region
maintained the lowest prevalence throughout the study period (11.34% to 12.85%).
The trend in annual state-wide DM prevalence followed an increasing pattern,
particularly among southeastern states and Puerto Rico. From 2006 to 2011, the
number of states in the DM prevalence range of 15%-20% increased from 6 in 2006
(West Virginia, Nevada, Indiana, Missouri, Rhode Island, Oklahoma) to 25 states in
2011. Alaska and Hawaii were the only states to maintain prevalence below 10% in
the 6-year study.CONCLUSIONS:The uneven distribution of DM toward southeast-
ern states suggests a geographic variation in risk areas that may be useful for future
targeted intervention strategies.
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OBJECTIVES: To investigate whether nutritional, life-style or behavioural interven-
tions during pregnancy or early life alter risk factors of developing metabolic syn-
drome and diabetes mellitus and to gain knowledge about the burden of the dis-
ease in population of Bangladesh, India and Pakistan. METHODS: A systematic
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intoler-
ance, diabetes-mellitus, pregnancy, fetal development, life-style, nutrition) was
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library
databases. It was completed by pearling and hand-searching. Two reviewers as-
sessed independently the results retrieved in the search, to adopt a decision on
inclusion/exclusion. The quality of included papers was appraised with STROBE
checklist for observational studies and Centre for Evidence Based Medicine check-
lists for any other study design. The present review is part of the GIFTS project
funded by Seventh Framework Programme of European Commission. RESULTS:
The search strategy identified a total of 3,278 papers. After exclusion by title, ab-
stract or duplicated 424 full text articles were retrieved. Up to now we have as-
sessed the 138 latest published papers, excluding 37. Of the 101 included articles 8
were randomized controlled trials, mainly focused on improving maternal and
fetal outcomes with nutritional supplementation, but also with community-based
interventions. There were another 47 observational studies, including long term
follow-up cohorts, which established relationship between fetal development and
posterior increased risk of metabolic syndrome for mothers and offspring. The
other ones are reviews, most of them narrative reviews, heightening the burden of
disease in these countries, the relevance of the pregnancy period, and the necessity
of implement preventing strategies. CONCLUSIONS: Metabolic syndrome is a
health problem of great magnitude in Bangladesh, India and Pakistan. As early life
determinants of the disease are clearly stated, it would be important to now design
feasible and cost-effective interventions to prevent disease.
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OBJECTIVES: To determine the population attributable risk (PAR) of microvascular
events associated with HbA1c, systolic blood pressure (SBP), or body mass index
(BMI)in patients with type 2 diabetes mellitus (T2DM). METHODS: From the
PHARMO database 6010 T2DM patients were followed in the period 2000-2008 after
at least 6 months of antidiabetic treatment (median 25, iqr 9-51 months). Survival
models based on regularly monitored risk factors, other characteristics and regis-
tered complications were used to estimate the expected number of complications
(renal failure, retinopathy, ulcers / amputations) after 5 years (base-case). The
estimated number of averted cases after reducing risk factors divided by the base-
case number resulted in the PAR. RESULTS: Mean age was 66 years (SD 12), 55%
were men. 45% had elevated HbA1c (7.0%), averaging 7.8% (SD 0.8). HbA1c reduc-
tions of 0.5% or to target (7.0%) led to significant case reductions of renal failure of
3% and 5% and of retinopathy by 6% and 10%, respectively. 66% had elevated SBP
(140 mmHg), averaging 161 mmHg (sd 16). SBP was not significantly associated
with microvascular complications. 85% had elevated BMI (25.0 kg/m2) averaging
30.7 kg/m2 (SD 4.5). BMI reductions of 10% (mean 8.7 kg) or to target (25.0 kg/m2,
mean 15.8 kg) led to significant case reductions of ulcers of 20% and 35%, but an
increase of retinopathy of 7% and 12%, respectively.Eliminating all risk factors in
the model would have averted 99 out of 493 renal failure cases (PAR 20%), 148 out of
566 ulcer cases (PAR 26%) and 21 out of 580 retinopathy cases (PAR 4%) after 5 years.
Reductions of 0.5% HbA1c, 10 mmHg SBP and 10% BMI would have averted 11% of
renal failure, 16% of ulcers and 1% of retinopathy. CONCLUSIONS: Even modest
changes in HbA1c and BMI led to significant reductions in microvascular compli-
cations.
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OBJECTIVES: To identify recent data describing the long-term risk of complications
in patients with type 1 diabetes mellitus (T1DM), and their association with glyco-
sylated haemoglobin (HbA1c) and other risk factors, and to select complications
and related data for inclusion in a new cost-utility model for T1DM. METHODS: A
systematic review was performed. The following electronic databases were
searched (1 January 2003-27 July 2011): MEDLINE, MEDLINE In-Process, EMBASE,
and the Cochrane Library, including the Health Technology Assessment (HTA)
database. Relevant clinical guidelines and HTA documentation were also searched.
RESULTS: A total of 4,846 titles were screened; 281 reports of 72 unique studies
were included for qualitative synthesis. Multiple reports were identified for several
studies, including the Diabetes Control and Complications Trial and the Epidemi-
ology of Diabetes Interventions and Complications follow-up study (DCCT/EDIC),
the Epidemiology of Diabetes Complications (EDC) study, the Finnish Diabetic Ne-
phropathy (FinnDiane) Study, the Wisconsin Epidemiologic Study of Diabetic Ret-
inopathy, the EURODIAB type 1 complications study, and several other large obser-
vational and registry studies. Data were extracted for 57 T1DM complications in
adults and 20 in children and adolescents. Complications were selected for inclu-
sion in the cost-utility model where there was evidence for a statistical association
with T1DM and HbA1c levels, an impact on mortality, and an expected impact on
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